Fig. 7 | Scientific Reports

Fig. 7

From: Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer

Fig. 7

Expression values of the eight validated biomarkers on the protein and transcriptional level. Bar charts show the mean log2FC on protein and cellular and cell-free RNA level measured by label-free proteomics (left, a, c, e, g only) total RNA-Seq (second from left in a, c, e, g and left in b, d, f, h, cellular RNA only) and RT-qPCR (second from right: cellular RNA, right: cfRNA). Error bars represent the SEM, and asterisks indicate significant changes with p-values < 0.05 (*), < 0.01 (**) and < 0.001 (***) as assessed by Student’s t-test with Benjamini–Hochberg multiple testing correction (proteomics) and one-way ANOVA (RNA-Seq and RT-qPCR). For ANOVA, Dunnett’s post-test was used to compare treatment with the DMSO control, while the different vandetanib concentrations were compared using Tukey’s post-test. Each diagram shows the data for a different biomarker candidate gene: NDRG1 (a), FOXM1 (b), ISG20 (c), TPX2 (d), AHNAK2 (e), MYBL2 (f), THBD (g), and GPRC5C (h). FOXM1, TPX2, MYBL2, and GPRC5C were not detected on protein level.

Back to article page